Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Vinci Compass Investments Ltd.
13G
VINP · G9451V109
|
6.0% |
8/14/2026
Event 6/30/2026
|
|||
| Samlyn Capital, LLC | 6.0% | ||||
| Samlyn, LP | 6.0% | ||||
| Robert Pohly | 6.0% | ||||
|
PureCycle Technologies, Inc.
13G/A
Amendment 6
PCT · 74623V103
|
4.2% |
5/15/2026
Event 3/31/2026
|
|||
| Samlyn Capital, LLC | 4.2% | ||||
| Samlyn, LP | 4.2% | ||||
| Robert Pohly | 4.2% | ||||
|
PureCycle Technologies, Inc.
13G/A
Amendment 5
PCT · 74623V103
|
7.2% |
11/14/2025
Event 9/30/2025
|
|||
| Samlyn Capital, LLC | 7.2% | ||||
| Samlyn, LP | 7.2% | ||||
| Robert Pohly | 7.2% | ||||
|
PureCycle Technologies, Inc.
13G/A
Amendment 4
PCT · 74623V103
|
8.8% |
8/14/2025
Event 6/30/2025
|
|||
| Samlyn Capital, LLC | 8.8% | ||||
| Samlyn, LP | 8.8% | ||||
| Robert Pohly | 8.8% | ||||
|
Corvus Pharmaceuticals, Inc.
13G/A
Amendment 5
CRVS · 221015100
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| Samlyn Capital, LLC | 0% | ||||
| Samlyn, LP | 0% | ||||
| Robert Pohly | 0% | ||||
|
Vinci Partners Investments Ltd.
13G/A
Amendment 3
VINP · G9451V109
|
4.8% |
5/15/2025
Event 3/31/2025
|
|||
| Samlyn Capital, LLC | 4.8% | ||||
| Samlyn, LP | 4.8% | ||||
| Robert Pohly | 4.8% | ||||
|
Nektar Therapeutics
13G/A
Amendment 1
NKTR · 640268108
|
0% |
5/15/2025
Event 3/31/2025
|
|||
| Samlyn Capital, LLC | 0% | ||||
| Samlyn, LP | 0% | ||||
| Robert Pohly | 0% | ||||
|
Corvus Pharmaceuticals, Inc.
13G/A
Amendment 4
CRVS · 221015100
|
6.0% |
5/15/2025
Event 3/31/2025
|
|||
| Samlyn Capital, LLC | 6.0% | ||||
| Samlyn, LP | 6.0% | ||||
| Robert Pohly | 6.0% | ||||
|
Vinci Partners Investments Ltd.
13G/A
Amendment 2
VINP · G9451V109
|
6.2% |
2/14/2025
Event 12/31/2024
|
|||
| Samlyn Capital, LLC | 6.2% | ||||
| Samlyn, LP | 6.2% | ||||
| Robert Pohly | 6.2% | ||||
|
Inozyme Pharma, Inc.
13G/A
Amendment 1
INZY · 45790W108
|
0% |
2/14/2025
Event 12/31/2024
|
|||
| Samlyn Capital, LLC | 0% | ||||
| Samlyn, LP | 0% | ||||
| Robert Pohly | 0% | ||||
|
PureCycle Technologies, Inc.
13G/A
Amendment 3
PCT · 74623V103
|
6.5% |
2/14/2025
Event 12/31/2024
|
|||
| Samlyn Capital, LLC | 6.5% | ||||
| Samlyn, LP | 6.5% | ||||
| Robert Pohly | 6.5% | ||||
|
Corvus Pharmaceuticals, Inc.
13G/A
Amendment 3
CRVS · 221015100
|
9.8% |
2/14/2025
Event 12/31/2024
|
|||
| Samlyn Capital, LLC | 9.8% | ||||
| Samlyn, LP | 9.8% | ||||
| Robert Pohly | 9.8% | ||||
|
Nektar Therapeutics
13G
NKTR · 640268108
|
5.2% |
2/14/2025
Event 12/31/2024
|
|||
| Samlyn Capital, LLC | 5.2% | ||||
| Samlyn, LP | 5.2% | ||||
| Robert Pohly | 5.2% | ||||